Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology:

Prof Marco Valgimigli (Cardiocentro Ticino Foundation, CH) joins us to share the 15-month results from the MASTER DAPT trial (NCT03023020).

This randomised, multi-centre study compared abbreviated antiplatelet with prolonged antiplatelet regimen (aspirin and P2Y12i) aligned with current medical recommendations in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS).

Questions:
1. What is the importance of the MASTER DAPT trial?
2. What was the data at 15 months and what does it add to the existing evidence?
4. What are your recommendations for clinical practice?
3. What are the future directions in antiplatelet therapy among PCI patients?
5. What are some of the unanswered questions in HBR and DAPT?

Recorded on-site at ESC Congress 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ESC 22: MASTER DAPT Results at 15M with Prof Valgimigli" передвинте ползунок вправо